Cost savings with hemin versus givosiran for the treatment of patients with acute intermittent porphyria (AIP)
Sign Up to like & getrecommendations! Published in 2020 at "Journal of Medical Economics"
DOI: 10.1080/13696998.2020.1835306
Abstract: Abstract Objective Since 1983, hemin has been FDA-approved for acute intermittent porphyria (AIP) attacks. In 2019, FDA approved givosiran for the treatment of adults with acute hepatic porphyria. The objective of this research was to… read more here.
Keywords: aip; treatment; givosiran treatment; hemin ... See more keywords
Givosiran for the treatment of acute hepatic porphyria
Sign Up to like & getrecommendations! Published in 2022 at "Expert Review of Clinical Pharmacology"
DOI: 10.1080/17512433.2022.2075848
Abstract: ABSTRACT Introduction Acute hepatic porphyrias (AHPs) are a family of rare inherited disorders characterized by enzyme dysfunctions in the hepatic pathway of heme biosynthesis. In AHPs, accumulation of the neurotoxic porphyrin precursors delta-aminolevulinic acid and… read more here.
Keywords: givosiran; acute hepatic; hepatic porphyria; givosiran treatment ... See more keywords